Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron
emission tomography (PET) and single-photon imaging, including single-photon emission …

Recent Food and Drug Administration (FDA) approval of diagnostic and therapeutic
radiopharmaceuticals and concurrent miniaturization of particle accelerators leading to …

Abstract Rationale: Small 225 Ac-labeled prostate-specific membrane antigen (PSMA)-
targeted radioconjugates have been described for targeted alpha therapy of metastatic …

Although radioactive experiments are necessary in radiopharmaceutical drug discovery and
theranostic cancer research, they are expensive, require special facilities, and face certain …

Prostate-specific membrane antigen (PSMA), highly expressed in prostate cancer, is a
promising target for radionuclide therapy. Auger electron-emitting radionuclides are well …

Simple Summary In nuclear medicine, therapeutic methods are used increasingly, in which
tumors are destroyed by ionizing radiation that cannot or can only be treated insufficiently by …

The aim of this review is to make the reader familiar with currently available radiometals,
their production modes, capacities, and quality concerns related to their medical use, as well …

Cobalt–sarcophagine complexes exhibit high kinetic inertness under various stringent
conditions, but there is limited literature on radiolabeling and in vivo positron emission …

The emerging success of [68Ga/177Lu] Ga/Lu-DOTATATE as a theranostic pair has spurred
interest in other isotopes as potential theranostic combinations. Here, we review cobalt-55 …

Abstract Positron-emission-tomography (PET) has become an indispensable diagnostic tool
in modern nuclear medicine. Its outstanding molecular imaging features allow repetitive …